Placebo Research at the
UCLA Neuropsychiatric Institute
Placebo Research Home

Q & A about Placebos (FAQ)

Our Research Team

Press Releases & News

Scientific Publications

Research Team at UCLA
Andrew F. Leuchter, M.D., leads the research team investigating placebo effects at the NPI. Dr. Leuchter is the Daniel X. Freedman Professor and Vice Chair of the Department of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute and Hospital. In his role as Vice Chair Dr. Leuchter oversees teaching, clinical care, and clinical research of patients with depression, psychosis, anxiety, and other mental illnesses throughout UCLA Medical Center. He also serves as Chief of Staff for the UCLA Neuropsychiatric Hospital, and Director of Continuing Education for the UCLA Neuropsychiatric Institute.

Dr. Leuchter received his undergraduate degree from Stanford University, and his medical degree from the Baylor College of Medicine. He completed his residency at the UCLA Neuropsychiatric Institute, and a Robert Wood Johnson Fellowship in the UCLA Department of Medicine.

Dr. Leuchter's clinical expertise is in the treatment of depression, with a special focus on treatment-resistant and late-life depression. Using brain imaging techniques such as quantitative electroencephalography (QEEG), magnetic resonance imaging (MRI), and positron emission tomography (PET), Dr. Leuchter examines brain function to predict which treatments are most likely to benefit individual patients. His research program combines clinical trials with neurophysiologic and brain imaging studies to inform clinical practice in the treatment of depression.

Dr. Leuchter is Board Certified in Psychiatry, has Added Qualifications in Geriatric Psychiatry and is Board Certified in Electroencephalography. He is the author of numerous articles and chapters on the assessment and treatment of depression, dementia and other major mental illnesses, and is the author of two patents for new methods to analyze brain electrical activity.


Ian A. Cook, M.D. is co-Investigator with Dr. Leuchter of the research team investigating placebo effects at UCLA. Dr. Cook is a Research Scientist at the UCLA Neuropsychiatric Institute, the founding Director of the UCLA NPI Academic Information Technology Core, and an Associate Professor of Psychiatry at the David Geffen School of Medicine at UCLA He was honored by the NIH as an NCDEU New Investigator in 1997 and received two NARSAD Young Investigator Awards to support his early-career research in depression and neurophysiology. He was the recipient of a Career Development Award from the NIMH to study factors leading to the side effects of psychoactive medications, and continues with NIMH funding as Principal Investigator for an R01 collaborative project joining UCLA/NPI and Massachusetts General Hospital to study "Response Variability in Treatment Resistant Depression." He has spoken internationally and published peer-reviewed research on depression and brain function.

Dr. Cook's clinical focus is on the treatment of mood and cognitive disorders. His research projects use measures of brain structure (MRI) and of brain function (EEG, fMRI, PET) to learn more about how brain factors influence the particular symptoms and side effects that patients experience and their response to treatment. His publication list is online here.

Dr. Cook received his bachelors degree with high honors from Princeton University and his medical degree from the Yale University School of Medicine. He completed his psychiatry residency training at UCLA's Neuropsychiatric Institute, where he also was an NIMH-funded research fellow. Since joining the faculty, he has been honored three times with departmental teaching awards. He led the NPI's Internet Initiative to use innovations in information technology to extend the reach of educational programs, and is the architect of the online CME programs at the Neuropsychiatric Institute. He holds four patents on biomedical devices and methods.

Dr. Cook serves on the Executive Committee on Practice Guidelines of the American Psychiatric Association, and leads their work in electronic dissemination of evidence-based guidelines in psychiatry. He is also a member of the Executive Board of the West Coast College of Biological Psychiatry, where he serves as Communications Chair. A board-certified Psychiatrist, he is an examiner for the American Board of Psychiatry and Neurology. His biography is profiled in Who's Who in America and Who's Who in the World.


Aimee M. Hunter, Ph.D. is a research psychologist on the placebo investigative team at UCLA. Dr. Hunter received both her undergraduate and graduate degrees in Psychology from UCLA. Her graduate work focused on behavioral neuro-pharmacology in the learned helplessness paradigm, an expectation-related model of depression. More recently, Dr. Hunter has turned to explore the roles of expectation and brain changes during brief placebo treatment as they relate to antidepressant side effects and clinical outcome. She currently holds a Psychobiology Research Fellowship from the National Institute of Mental Health (NIMH). Dr. Hunter was awarded a 2004 New Investigator Award from the NIMH New Clinical Drug Evaluation Unit (NCDEU) for her work examining brain changes during placebo lead-in and treatment outcomes in clinical trials for major depression.

Melinda L. Morgan, Ph.D., MSW, is an assistant professor in the department of Psychiatry and Biobehavioral Sciences at the UCLA Neuropsychiatric Institute and Hospital. As a member of the research team investigating placebo effects, her interests are focused on physiologic and psychosocial predictors of placebo response in depression. She has an overarching interest in women’s mental health across the life span. Her recent work focuses on intervention research in depression in women during the transition to menopause. She has received two NARSAD Young Investigator’s Awards in addition to the NCDEU New Investigator’s Award in 2003 to support her research in perimenopausal depression and estrogen augmentation of antidepressant medication. She was an NIMH postdoctoral fellow and a geriatric research scholar at the NIMH Summer Research Institute. During graduate school at UCLA she studied cognitive and hormonal functioning in premenstrual dysphoric disorder. Currently she is expanding her research to study changes in neuroactive steroids during menopause in women being treated with medication versus placebo.

 

[ Neuropsychiatric Institute Home ]     [ QEEG Lab Home ]